TBPH · As filed with the SEC
Theravance Biopharma cash flow statement, by fiscal year
The statement as Theravance Biopharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 |
|---|---|---|
| Operating activities | ||
| Net income (loss) | 105,895,000 | (56,418,000) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||
| Depreciation and amortization | 1,626,000 | 1,710,000 |
| Amortization and accretion on investment securities, net | (2,830,000) | (2,509,000) |
| Future royalty payment contingency interest accretion | 2,461,000 | 2,546,000 |
| Share-based compensation | 18,476,000 | 21,393,000 |
| Loss on disposal of property and equipment | 35,000 | 34,000 |
| Loss on impairment of long-lived assets | 0 | 4,513,000 |
| Amortization of right-of-use assets | 4,015,000 | 4,414,000 |
| Deferred income taxes | (11,519,000) | (7,573,000) |
| Other | (89,000) | — |
| Changes in operating assets and liabilities: | ||
| Receivables from collaborative and licensing arrangements | (27,099,000) | (966,000) |
| Prepaid clinical and development services | 73,000 | 1,965,000 |
| Other prepaid and current assets | (3,360,000) | 7,399,000 |
| Right-of-use lease assets | (32,000) | (707,000) |
| Future contingent milestone and royalty assets | 144,200,000 | — |
| Other assets | (1,077,000) | 411,000 |
| Accounts payable | 326,000 | 750,000 |
| Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities | 4,009,000 | 1,468,000 |
| Operating lease liabilities | (7,117,000) | 661,000 |
| Unrecognized tax benefits | 10,481,000 | 9,906,000 |
| Other long-term liabilities | 67,000 | (532,000) |
| Net cash provided by (used in) operating activities | 238,541,000 | (11,535,000) |
| Investing activities | ||
| Purchases of property and equipment | (42,000) | (332,000) |
| Purchases of marketable securities | (248,217,000) | (140,743,000) |
| Maturities of marketable securities | 142,975,000 | 139,813,000 |
| Purchase of derivative | — | (2,292,000) |
| Sale of short-term investments and marketable securities | — | 15,838,000 |
| Net cash (used in) provided by investing activities | (105,284,000) | 12,284,000 |
| Financing activities | ||
| Ordinary share repurchases | — | (445,000) |
| Proceeds from the sale of ordinary shares | 20,000 | 99,000 |
| Proceeds from ESPP purchases | — | 508,000 |
| Proceeds from option exercises | 766,000 | — |
| Repurchase of shares to satisfy tax withholding | (4,034,000) | (2,659,000) |
| Net cash used in financing activities | (3,248,000) | (2,497,000) |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 130,009,000 | (1,748,000) |
| Cash, cash equivalents, and restricted cash at beginning of period | 38,633,000 | 40,381,000 |
| Cash, cash equivalents, and restricted cash at end of period | 168,642,000 | 38,633,000 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for income taxes, net | 27,884,000 | 109,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.